Single-Use Bioprocessing technology and investment research

Technical bottleneck

Why the bag film is the product — and the moat

A single-use bioreactor bag is not a commodity plastic bag. It is a highly engineered multilayer film that must simultaneously:

Gas transfer (O₂ in, CO₂ out):

Mammalian cells (CHO, HEK293) respire — they consume oxygen and produce carbon dioxide. The bag film must permit sufficient gas transfer to maintain dissolved oxygen at 30–50% of air saturation and pCO₂ below inhibitory levels (typically <80 mmHg). This is achieved through careful selection of film polymers (typically polyethylene/EVOH multilayers) with known O₂ and CO₂ permeability coefficients. Too permeable → sterility risk. Too impermeable → cells suffocate.

Extractables and leachables (E&L):

Every chemical species that migrates from the plastic into the drug product is a potential patient safety risk. USP <87> (biological reactivity), USP <88> (Class VI plastics), and ICH Q3C/Q3D (residual solvents / elemental impurities) define the testing framework. A single-use bag must pass:

• Extraction studies under worst-case conditions (elevated temperature, extended contact time, aggressive solvents)
• Leachables studies under actual process conditions (cell culture media at 37°C for 14–21 days, then harvest and purification)
• Comprehensive analytical characterization: GC-MS for volatiles, LC-MS for semi-volatiles/non-volatiles, ICP-MS for elemental impurities

This is a 12–18 month characterization exercise before a film is even considered for GMP use. Once qualified, the film is in the drug's regulatory filing — the qualification moat.

Mechanical integrity:

A 2,000 L bioreactor bag contains two metric tons of liquid under mixing. The bag film must withstand:

• Rocking or stirring forces for 14–21 days without delamination or pinhole formation
• Gamma irradiation (25–40 kGy) for sterilization without polymer degradation
• Freeze-thaw cycles if cells or drug substance are stored frozen
• Welded tubing connections (tube welding creates the sterile fluid path between bags) without leaks

The gamma sterilization constraint:

Single-use systems are sterilized by gamma irradiation at 25–40 kGy. Many polymers degrade at these doses — becoming brittle, discolored, or generating elevated E&L. The film formulation must be stable through gamma while maintaining the gas transfer and mechanical properties listed above. This eliminates most commodity plastics.

Why the qualification moat is the same as chromatography resins

Once a single-use bag film, tubing set, or connector is named in a drug's IND/BLA, the supplier's part number is in the regulatory filing. Changing to a different supplier's film requires:

• Supplier audit and quality agreement: 3–6 months
• Material characterization (E&L, mechanical, gas transfer): 6–12 months
• Process qualification (small-scale model, engineering runs): 6–12 months
• Comparability protocol and regulatory filing: 6–12 months
• Total: 18–36 months, $2–5M, and risk of regulatory rejection

Result: vendors become partners for the drug's commercial lifetime.

Adoption

Why it matters now

Flexible facility demand:

The pipeline is shifting toward smaller-volume, higher-value biologics (ADCs, bispecifics, cell/gene therapies) that don't justify dedicated stainless steel facilities. Single-use enables a single facility to manufacture 5–10 different products — the capex is lower, the changeover is faster, and the regulatory pathway is simpler for multi-product facilities.

GLP-1 manufacturing demand:

While GLP-1s are primarily synthetic peptides (not requiring cell culture), the broader manufacturing ecosystem — single-use for formulation, buffer preparation, and fill-finish intermediates — benefits from the same capacity constraints. Every drug needs sterile fluid handling.

The Entegris crossover:

Entegris is the purest single-use crossover play. Their semiconductor heritage in ultra-high-purity fluid handling (ppb-level contamination control in chip fabs) translates directly to bioprocessing, where contamination means batch loss. The same materials science that controls particles and extractables in semiconductor chemicals applies to cell culture media and buffer solutions.

Key players

Horizon

• Horizon 1 (0–2yr): Single-use capacity expansion to meet biologics pipeline demand; GLP-1 manufacturing pulling single-use consumables; Entegris life sciences segment growth
• Horizon 2 (3–5yr): Continuous bioprocessing with single-use flow paths (perfusion, multi-column chromatography); autonomous closed-loop manufacturing; sensor-integrated smart bags
• Horizon 3: Cell-free manufacturing eliminates single-use bioreactors entirely (but creates new consumable categories); printed/3D-manufactured single-use components at point of use

Related Technologies

• Bioprocessing Consumables — the broader consumables ecosystem; single-use bags are upstream, chromatography resins are downstream
• Sterile Fill-Finish — single-use assemblies for drug product formulation and filling